VR Logo

Unrated

Tata India Pharma & HealthCare Fund - Direct Plan


1 Lakh

Investment Grown to
₹ 2.12 Lakh

₹ 10000

Monthly SIP Grown to
₹ 5.82 Lakh

Suitability:

"This is a fund that invests mainly in shares of pharmaceutical and healthcare companies.

We believe that investors should avoid funds that have a narrowly defined investment mandate such as this one. Instead, they should invest in multi-cap funds which provide complete freedom to the fund management team to invest in companies from which it expects maximum gains.

But if you do invest, you must do so only through the SIP route. Click here to read a primer on SIP investing.

Warning: Do not invest in this, or any other pharma sector fund, if you need to redeem your investment in less than seven years."

Taxability of earnings:

Capital gains

  • If the mutual fund units are sold after 1 year from the date of investment, gains upto Rs 1 lakh in a financial year are exempt from tax. Gains over Rs 1 lakh are taxed at the rate of 10%.
  • If the mutual fund units are sold within 1 year from the date of investment, entire amount of gain is taxed at the rate of 15%.
  • No tax is to be paid as long as you continue to hold the units.

Dividends

  • Dividends are added to the income of the investors and taxed according to their respective tax slabs. Further, if an investor's dividend income exceeds Rs. 5,000 in a financial year, the fund house also deducts a TDS of 10% before distributing the dividend.

Read more

ajax-loader
Please wait...

ajax-loader
Please wait...

(₹)
cal
cal

ajax-loader
Please wait...

Trailing Returns (%)

YTD 1-Day 1-W 1-M 3-M 6-M 1-Y 3-Y 5-Y 7-Y 10-Y
Fund 15.84 0.36 -0.92 -2.45 -0.48 9.98 28.80 28.56 14.93 -- --
S&P BSE Healthcare TRI 17.57 0.62 -0.56 -2.12 -1.24 8.98 29.68 23.04 10.00 -- --
Equity: Sectoral-Pharma 17.42 0.37 -0.64 -2.03 0.02 10.25 30.12 28.84 13.90 -- --
Rank within category 7 6 9 8 6 6 6 3 2 -- --
Number of funds in category 10 10 10 10 10 10 9 6 4 3 0

As on 27-Oct-2021

Peer Comparison

Fund name Rating Launch Date 1-Year Return 3-Year Return 5-Year Return Expense Ratio Assets (Cr)
Tata India Pharma & HealthCare Fund - Direct Plan  | Invest Online
Unrated
Dec-15 28.80 28.56 14.93 1.06% 590
Nippon India Pharma Fund - Direct Plan
Unrated
Jan-13 34.58 28.20 16.74 0.90% 5,474
ICICI Prudential Pharma Healthcare And Diagnostics (P.H.D) Fund - Direct Plan  | Invest Now
Unrated
Jul-18 30.50 29.35 -- 1.04% 3,074
SBI Healthcare Opportunities Fund - Direct Plan  | Invest Online
Unrated
Jan-13 27.70 26.04 10.99 1.07% 2,001
Mirae Asset Healthcare Fund - Direct Plan  | Invest Online
Unrated
Jul-18 34.38 33.91 -- 0.55% 1,885

Best & Worst Performance

Best Performance Worst Performance
Return (%) Period Return (%) Period
Week 20.45 01-Apr-2020 - 09-Apr-2020 -11.10 05-Mar-2020 - 12-Mar-2020
Month 31.75 27-Mar-2020 - 27-Apr-2020 -18.30 20-Feb-2020 - 23-Mar-2020
Quarter 38.52 23-Mar-2020 - 22-Jun-2020 -14.24 26-Sep-2016 - 26-Dec-2016
Year 76.35 23-Mar-2020 - 23-Mar-2021 -17.32 08-Sep-2016 - 08-Sep-2017

Risk Measures (%)

Mean Std Dev Sharpe Sortino Beta Alpha
Fund 25.58 17.81 1.21 2.86 0.80 7.75
S&P BSE Healthcare TRI 21.34 21.63 0.80 1.76 -- --
Equity: Sectoral-Pharma 26.10 19.71 1.12 2.60 0.89 6.63
Rank within category 3 1 2 2 1 2
Number of funds in category 6 6 6 6 6 6

The Risk Measures have been calculated using calendar month returns for the last three years.

As on 30-Sep-2021

Asset Allocation (%)

ajax-loader
Please wait...

Concentration & Valuation

Number of Stocks 29
Top 10 Stocks (%) 69.13
Top 5 Stocks (%) 44.36
Top 3 Sectors (%) 99.22
Portfolio P/B Ratio 5.38
Portfolio P/E Ratio 35.86

Portfolio Aggregates

Fund Category
Average Mkt Cap (Rs Cr) 41,234 56,067
Giant (%) 12.11 15.32
Large (%) 33.99 40.40
Mid (%) 37.48 34.32
Small (%) 16.42 9.96
Tiny (%) -- --

Value Research Fund Style

Sector Allocation vis-à-vis Category

ajax-loader
Please wait...

Top Holdings

Company Sector P/E 3Y High 3Y Low % Assets
equal Sun Pharmaceutical Industries Healthcare 32.28 17.08 5.93 12.02
equal Dr. Reddy's Lab Healthcare 43.80 17.99 7.57 8.56
equal Divi's Laboratories Healthcare 66.50 10.88 6.37 8.50
equal Cipla Healthcare 27.80 9.44 0.00 8.33
down Alkem Laboratories Healthcare 26.98 7.08 0.00 6.95
up Ipca Laboratories Healthcare 26.94 11.01 4.51 6.49
up Apollo Hospitals Healthcare 72.82 6.51 1.80 6.40
up Narayana Hrudayalaya Healthcare 58.52 7.17 0.00 4.73
up Lupin Healthcare -- 10.47 1.93 3.60
equal Fortis Healthcare Healthcare 56.38 4.74 0.00 3.55
equal JB Chemicals & Pharma Healthcare 28.41 3.26 0.00 3.26
equal Krishna Institute Of Medical Sciences Healthcare 45.73 2.47 0.00 2.42
equal Procter & Gamble Health Healthcare 51.08 7.30 2.32 2.38
equal FDC Healthcare 17.36 2.37 0.00 2.24
equal Indoco Remedies Healthcare 35.75 3.39 0.00 2.12
equal Syngene International Healthcare 53.30 7.58 0.00 2.03
equal Metropolis Healthcare Healthcare 58.65 2.22 0.00 1.97
up Gland Pharma Healthcare 52.89 1.93 0.00 1.93
equal Abbott India Healthcare 60.26 11.41 0.00 1.77
equal Healthcare Global Enterprises Healthcare -- 2.94 0.00 1.72
down Ajanta Pharma Healthcare 27.12 2.04 0.00 1.64
equal Glenmark Pharma. Healthcare 13.61 1.96 0.00 1.44
down Aurobindo Pharma Healthcare 7.48 9.16 0.00 1.29
equal Laurus Labs Healthcare 27.34 5.05 0.00 0.94
equal Dr. Lal Pathlabs Healthcare 73.16 1.88 0.00 0.79

up down equal Indicates an increase or decrease or no change in holding since last portfolio
new Indicates a new holding since last portfolio

As on 30-Sep-2021

Fund Manager

— Meeta Shetty since 09-Nov-2018

Education: Ms. Shetty is Bachelor in Economics and CFA Charterholder

Experience: Prior to joining TATA Mutual Fund, she has worked with Kotak Securities, HDFC Securities, AMSEC(Asian Market Securities), Dalal & Broacha Stock Broking and karvey Stock Broking.

Funds Managed:


0.36%

Change from previous, NAV as on 27-Oct-2021

Growth: ₹ 19.0492

IDCW: ₹ 19.0492


Investment Strategy

The scheme seeks long term capital appreciation by investing atleast 80% of it's net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India.

Investment Details

Minimum Investment (₹) 5,000
Minimum Addl Investment (₹) 1,000
Minimum SIP Investment (₹) 150
Minimum No of Cheques 12
Minimum Withdrawal (₹) 500
Minimum Balance (₹) 500
Lock-in Period Not Applicable
Exit Load 0.25% for redemption within 30 days

Basic Details

Fund House: Tata Mutual Fund
Launch Date: 28-Dec-2015
Return Since Launch: 11.68%
Benchmark: NIFTY Pharma TRI
Riskometer: Very High
Type: Open-ended
Assets: ₹ 590 Cr (As on 30-Sep-2021)
Expense: 1.06% (As on 30-Sep-2021)
Risk Grade: --
Return Grade: --
Turnover: 40.92%

Contact Information

AMC: Tata Asset Management Private Ltd

Address: 9th Floor, Mafatlal Centre, Nariman Point, Mumbai - 400021

Phone: 1800-209-0101

Email: [email protected]

Website: http://www.tatamutualfund.com

Registrar & Transfer Agent: Computer Age Management Services Ltd.

Address: 7th Floor, Tower II, Rayala Towers, 158, Anna Salai, Chennai - 600002

Phone: 1800-3010-6767 / 1800-419-7676

Fax: 044-30407101

Email: [email protected]

Website: www.camsonline.com

Upcoming Video

Investors' Hangout

The investment mindset: These women show the way

DateFriday, 29-Oct-2021
Time12:30 PM - 01:00 PM